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Purpose
Etanercept has been approved in polyarticular juvenile
idiopathic arthritis (JIA) patients refractory or intolerant to
methotrexate. The objectives of the study were to evaluate
safety and efficacy of Etanercept and Methotrexate combi-
nation therapy versus Etanercept mono therapy in JIA
using a matched pair analysis.
Methods
A cohort of 1190 JIA patients enrolled in the German JIA
Enbrel registry has been used for screening. Matching cri-
teria included JIA subtype, gender, disease duration, use of
corticosteroids, oligo- versus polyarthritis at therapy start
and the sedimentation rate. Efficacy was determined using
the PedACR 30/ 50 and 70 response criteria. Safety assess-
ments were based on adverse events reports. The matched
data at month 1, 3, 6, 12, 18 and 24 on treatment have
been analyzed using the McNemar’s test.
Results
87 JIA matching pairs with a total of 658 visits have been
identified. No difference in PedACR 30/50/70 treatment
response between mono and combination therapy has
been found: month 1: 73%/61%/33% vs. 70%/61%/33%,
month 3: 73%/69%/51% vs. 65%/59%/41%; month 6: 82%/
77%/59% vs. 83%/72%/59%; month 12: 85%/78%/63% vs.
89%/80%/67%; month 18: 77%/73%/69% vs. 89%/81%/77%;
month 24: 63%/56%/50% vs. 56%/34%/34%. In the mono
therapy group 18 patients (21%) experienced 28 adverse
events. Five of them have been reported as serious. In the
combination group 19 patients (22%) experienced 30
adverse events. Seven of them have been reported as ser-
ious. No infectious serious adverse events occurred in the
mono therapy group compared to 3 in the combination
group. Two malignancies have been observed in the com-
bination group, none in the monotherapy group. Treat-
ment has been discontinued in 29 patients on mono
therapy (inefficacy 10%, adverse events 8%, remission 21%,
others 16%) compared to 51 patients in the combination
group (inefficacy 21%, adverse events 8%, remission 18%,
others 36%).
Conclusion
In contrast to the wide spread belief, combination treat-
ment with Etanercept and Methotrexate did not offer a
better outcome than treatment with Etanercept alone in
JIA patients who previously have been treated ineffectively
with methotrexate. However the rate of serious adverse
events, especially serious infections was slightly increased.
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